Literature DB >> 3467332

Tumorigenicity of hamster and mouse cells transformed by adenovirus types 2 and 5 is not influenced by the level of class I major histocompatibility antigens expressed on the cells.

H Haddada, A M Lewis, J A Sogn, J E Coligan, J L Cook, T A Walker, A S Levine.   

Abstract

Inbred hamster and mouse cells transformed by the nononcogenic adenovirus (Ad) serotypes, Ad2 and Ad5, are nontumorigenic in syngeneic adult animals, while cells from these species transformed by the highly oncogenic Ad12 are tumorigenic in such rodents. By immunoprecipitation and flow cytometry, cells from four of six Ad2- and Ad5-transformed hamster and mouse lines expressed high levels of cell-surface class I major histocompatibility complex (MHC) antigens, while cells from two of these six lines expressed low levels of cell-surface class I MHC antigens. The levels of class I MHC proteins expressed by cells from these latter two lines were comparable to the levels of cell-surface class I MHC proteins expressed by cells from Ad12-transformed hamster and mouse lines. Moreover, an Ad2-transformed line that had become highly oncogenic after in vivo adaptation showed the same high level of MHC expression as the nononcogenic parent. The amounts of class I mRNA, analyzed by RNA blotting, were, in general, consistent with the levels of class I antigens expressed on the surfaces of these cells. These results indicate that there is no correlation between the tumorigenicity in immunocompetent syngeneic adult rodents of Ad2- and Ad5-transformed hamster and mouse cells and the level of class I MHC antigens expressed on the surfaces of these cells. Thus, the expression of different levels of class I MHC proteins does not seem to explain the differences in the oncogenicity between nononcogenic and highly oncogenic human Ad serotypes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3467332      PMCID: PMC387205          DOI: 10.1073/pnas.83.24.9684

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Hybrid H-2 histocompatibility gene products assign domains recognized by alloreactive T cells.

Authors:  K Ozato; G A Evans; B Shykind; D H Margulies; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

4.  Patterns of integration of viral DNA in adenovirus type 2-transformed hamster cells.

Authors:  L Vardimon; W Doerfler
Journal:  J Mol Biol       Date:  1981-04-05       Impact factor: 5.469

5.  Structure and expression of a mouse major histocompatibility antigen gene, H-2Ld.

Authors:  G A Evans; D H Margulies; R D Camerini-Otero; K Ozato; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

6.  Host response to adenovirus 2-transformed hamster embryo cells.

Authors:  J L Cook; A M Lewis
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

7.  Primary structure of a murine transplantation antigen.

Authors:  J E Coligan; T J Kindt; H Uehara; J Martinko; S G Nathenson
Journal:  Nature       Date:  1981-05-07       Impact factor: 49.962

8.  An inverse relation of the oncogenic potential of adenovirus-transformed cells and their sensitivity to killing by syngeneic natural killer cells.

Authors:  K Raska; P H Gallimore
Journal:  Virology       Date:  1982-11       Impact factor: 3.616

9.  The quest for human cancer viruses.

Authors:  J J TRENTIN; Y YABE; G TAYLOR
Journal:  Science       Date:  1962-09-14       Impact factor: 47.728

10.  Spectrum of tumorigenic phenotypes among adenovirus 2-, adenovirus 12-, and simian virus 40-transformed Syrian hamster cells defined by host cellular immune-tumor cell interactions.

Authors:  A M Lewis; J L Cook
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

View more
  7 in total

1.  Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection.

Authors:  J L Cook; C K Krantz; B A Routes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

2.  Tumorigenicity and H-2 expression of papillomavirus-transformed mouse cell lines.

Authors:  A Laatikainen; H Karjalainen; H Jägerroos; H Sarkkinen; R Mäntyjärvi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Transcriptional and posttranscriptional regulation of class I major histocompatibility complex genes following transformation with human adenoviruses.

Authors:  J Shemesh; R Rotem-Yehudar; R Ehrlich
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

4.  Tumorigenicity of adenovirus-transformed rodent cells is influenced by at least two regions of adenovirus type 12 early region 1A.

Authors:  T Jelinek; D S Pereira; F L Graham
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

5.  Viral gene inhibition of class I major histocompatibility antigen expression: not a general mechanism governing the tumorigenicity of adenovirus type 2-, adenovirus type 12-, and simian virus 40-transformed Syrian hamster cells.

Authors:  H Haddada; J A Sogn; J E Coligan; M Carbone; K Dixon; A S Levine; A M Lewis
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

6.  Driving adenovirus type 12-transformed BALB/c mouse cells to express high levels of class I major histocompatibility complex proteins enhances, rather than abrogates, their tumorigenicity.

Authors:  S Soddu; A M Lewis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Downregulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12.

Authors:  R Rotem-Yehudar; S Winograd; S Sela; J E Coligan; R Ehrlich
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.